About
Science Corp., founded in 2021 in Alameda, USA, is a neurotechnology company developing retinal implants for treating eye diseases and brain implant systems.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-03Series C$230M
Investors · Y Combinator, Lightspeed, In-Q-Tel, Khosla Ventures, Quiet CapitalSource · SVTR Weekly #147 ↗
- 2025-04Debt / Convertible$104M
Investors · Khosla Ventures, Y Combinator, Quiet Capital, In-Q-TelSource · SVTR Weekly #101
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Science Corp.
Brain research technology company developing retinal and brain implant systems
Series C · $490M · 2026-03
$490M
United States
BusinessLatest roundTotal raisedDate- Synchron
Endovascularly implanted BCI that requires no open-brain surgery and helps paralyzed patients control digital devices
Series D+ · $200M · 2025-11
$200M - Neuralink
Focused on developing brain-computer interface technology
Undisclosed · $930M · 2025-06
$930M - Precision Neuroscience
building the next generation of brain-computer interfaces (BCIs) with a minimally invasive, high-density implant
Series D+ · $430M · 2026-09
$430M
China
BusinessLatest roundTotal raisedDate- SiClink
Founded in December 2025, SiClink is an implantable brain-computer interface company founded by ShanghaiTech University researcher Dr. He Fei. It develops semiconductor hollow flexible neural electrodes and a proprietary saline-based stiffness-modulation minimally invasive implantation process to build high-bandwidth, low-latency, long-term stable bidirectional brain-machine interfaces, starting with visual reconstruction.
— - StairMed
Developer of implantable brain-computer interface systems
Strategic · $153M · 2026-03
$153M - 神复健行
Implantable brain-spine interface to restore walking in paralyzed patients; products in FDA Breakthrough Device pathway
$42M
$42M
Europe
BusinessLatest roundTotal raisedDate- MintNeuro
Imperial College London spinout developing composable chip modules for neural signal acquisition, electrical stimulation, on-chip processing and wireless transmission, for BCI and active implant makers
Undisclosed · 2026-10
— - Neurosoft Bioelectronics
Flexible, stretchable, non-penetrating brain-computer interfaces and neural electrodes to record/stimulate brain-surface activity
Seed · $20M · 2026-05
$20M - InBrain Neuroelectronics
Graphene-based brain-computer interface technology for neurological disorders such as Parkinson's disease.
Series B · $50M · 2024-11
$50M
Other / unspecified
BusinessLatest roundTotal raisedDate- Vital Biosciences
Diagnostic technology developing the "revolutionary" blood test VitalOne
Undisclosed · $48M · 2023-07
$48M - Brain.space
Non-invasive brain monitoring platform with real-time neural data analysis
Series A · $11M · 2025-03
$11M - 脑思科技
Brain-computer interface electrodes and neural decoding systems
Angel · $10M · 2026-05
$10M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 14 at a nearby stage · 36 in United States
Request intro →Andreessen Horowitz
24 Life Sciences deals in the last 24 months · 12 at a nearby stage · 22 in United States
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 11 at a nearby stage · 15 in United States
Request intro →Lux Capital
15 Life Sciences deals in the last 24 months · 4 at a nearby stage · 15 in United States
Request intro →8VC
14 Life Sciences deals in the last 24 months · 7 at a nearby stage · 14 in United States
Request intro →Insight Partners
14 Life Sciences deals in the last 24 months · 4 at a nearby stage · 13 in United States
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.